Biotech firm Stem Cell Sciences is moving its administrative and operational division to its pharmaceuticals site at the Babraham Research Campus in Cambridge, England, in an effort to improve financial, operational and growth efforts, as well as increase focus on marketing strategies for its stem cell technologies. The stem cell pioneer will close its headquarters in Edinburgh, Scotland, and streamline operations in Melbourne, Australia.

Related Summaries